Precision BioSciences

Cindy Atwell, Senior Vice President, Business Development

Oct. 11 | 5:15pm | UBC Ballroom 

Durham, NC 

(NASDAQ: DTIL) 

In-person Presentation  

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer, rare diseases, and infectious diseases. 

www.precisionbiosciences.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions